Boston Scientific temporarily paused enrolment in its AVANT GUARD trial in October to “assess a few unanticipated ...

IMR is currently undertaking its Vision-MR Ablation of Atrial Flutter (VISABL-AFL) pivotal clinical trial supporting US FDA ...

Johnson & Johnson MedTech will enter the U.S. pulsed field ablation market following an FDA green light for its Varipulse ...

The prevalence of PH was 12.8% in those hospitalized in 2018 with left heart disease, a lower percentage than found in previous research.

Tempus, a leader in artificial intelligence and precision medicine, and Northwestern Medicine, Chicago’s premier integrated ...

p < 0.001], atrial fibrillation/flutter (AF) [cIRR 1.023, 95% CI 1.010-1.035, p<0.001], heart failure (HF) [cIRR 1.037, 95% CI 1.029-1.046, p < 0.001], myocardial infarction (MI) [cIRR 1.031, 95% CI 1 ...

Medtronic plc has announced United States Food and Drug Administration (FDA) approval of the Affera Mapping and Ablation ...

The incidence of atrial fibrillation (AF ... and patients with symptomatic or clinically significant atrial flutter. The previous iteration recommended trying drug therapy first.

Atrial flutter is "a type of heart rhythm disorder", according to the Mayo Clinic. It is also called an arrhythmia. According to the Mayo Clinic, it "is similar to atrial fibrillation" however ...

In the U.S., the approval covers the treatment of the irregular heartbeats caused by persistent afib as well as the ... isthmus-dependent atrial flutter. "The Affera system was designed to address ...